Purchases of stock-in-trade nearly doubled during the quarter, while other expenses rose around 45 per cent YoY, weighing on margins. The pharma business, which accounted for 78 per cent of consolidated revenue, reported sales of ₹6,090 crore, up 8.6 per cent YoY. The India formulations business registered revenue of ₹1,815.8 crore, up 19.5 per cent YoY, contributing 23 per cent of consolidated revenue. The North America formulations business reported revenue of ₹3,097.9 crore, down 2.6 per cent YoY, though it grew 4.9 per cent sequentially. The international markets formulations business posted revenue of ₹973.5 crore, up 34 per cent YoY, accounting for 12 per cent of consolidated revenue.